Ernest I Kohorn1. 1. Department Gynecology and Obstetrics, Yale University School of Medicine, New Haven, Connecticut, USA. ernest.kohorn@yale.edu
Abstract
OBJECTIVE: To determine whether protocols for the management of gestational trophoblastic neoplasia conform to the principles of evidence-based medicine. STUDY DESIGN: Protocols for the management of low- and high-risk gestational trophoblastic neoplasia were examined to determine to what extent they conformed to the principles of evidence-based medicine. RESULTS: Nearly all current chemotherapy regimens for gestational trophoblastic neoplasia are based on the experience of management of various risk groups, variously defined. Some prospective, randomized studies were flawed by faulty selection criteria. Local population variations may influence the results of management. CONCLUSION: The management of trophoblastic neoplasia is based on physician experience. Nearly all prospective, randomized studies have been flawed. There is a need for carefully planned prospective studies with stringent inclusion criteria to determine the most effective and cost-effective and least toxic therapy, particularly for low-risk neoplasia.
OBJECTIVE: To determine whether protocols for the management of gestational trophoblastic neoplasia conform to the principles of evidence-based medicine. STUDY DESIGN: Protocols for the management of low- and high-risk gestational trophoblastic neoplasia were examined to determine to what extent they conformed to the principles of evidence-based medicine. RESULTS: Nearly all current chemotherapy regimens for gestational trophoblastic neoplasia are based on the experience of management of various risk groups, variously defined. Some prospective, randomized studies were flawed by faulty selection criteria. Local population variations may influence the results of management. CONCLUSION: The management of trophoblastic neoplasia is based on physician experience. Nearly all prospective, randomized studies have been flawed. There is a need for carefully planned prospective studies with stringent inclusion criteria to determine the most effective and cost-effective and least toxic therapy, particularly for low-risk neoplasia.
Authors: Raymond J Osborne; Virginia Filiaci; Julian C Schink; Robert S Mannel; Angeles Alvarez Secord; Joseph L Kelley; Diane Provencher; David Scott Miller; Allan L Covens; Janice M Lage Journal: J Clin Oncol Date: 2011-01-24 Impact factor: 44.544